Announcement on Obtaining Domestic Production Drug Registration Certificate for Cooperative Product Ageropine Sodium Injection

Zhejiang Xianju Pharmaceutical Co., Ltd.·July 1, 2026·2 pages

✨ AI Summary

Zhejiang Xianju Pharmaceutical Co., Ltd. announces it has obtained a domestic production drug registration certificate for Ageropine Sodium Injection, a cooperative product with Hangzhou Aumor Pharmaceutical Co., Ltd. Hangzhou Aumor is the marketing authorization holder, while Xianju Pharmaceutical holds the API approval. The product has been included in the pre-申报 list for national medical insurance.

Summary generated by AI · Always verify with source document

Full Translation

AI Translation· gemini_document

Securities Code: 002332

Securities Abbreviation: Xianju Pharmaceutical

Announcement Number: 2026-036

Zhejiang Xianju Pharmaceutical Co., Ltd.

Announcement on Obtaining Domestic Production Drug Registration Certificate for Cooperative Product Ageropine Sodium Injection

The Company and all members of the Board of Directors guarantee the truthfulness, accuracy, and completeness of the information disclosed, and there are no false records, misleading statements, or major omissions.

Zhejiang Xianju Pharmaceutical Co., Ltd. (hereinafter referred to as the "Company") and Hangzhou Aumor Pharmaceutical Co., Ltd. (hereinafter referred to as "Hangzhou Aumor") have recently obtained the "Drug Registration Certificate" (Certificate Number: 2026S02323) issued by the National Medical Products Administration for their cooperative product Ageropine Sodium Injection (Omeracson Sodium Injection).

Free accounts get 10 full releases per month. Pro subscribers get unlimited access.